Bernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Bernstein's top two SMID biotech picks for 2025
January 8, 2025 6:00 PM ESTBernstein analysts identified Biohaven Pharma (NYSE: BHVN) and Beam Therapeutics Inc. (NASDAQ: BEAM) as their top small- to mid-cap (SMID) biotech picks for 2025, citing promising developments in their respective platforms.
Bernstein expresses "high conviction" in Biohavens degrader platform, with an update expected in the first quarter of 2025.
They highlight... More
